top of page

Chames Kermi, PharmD, PhD, MBA

PARTNER
LIFE SCIENCES

Chames Kermi focuses on sourcing, evaluating, and supporting investment opportunities across biotechnology, biopharmaceuticals, healthtech, and emerging healthcare technologies. He brings more than a decade of experience spanning drug development, translational science, venture evaluation, and company creation, with particular expertise in oncology, regenerative medicine, and AI-enabled life sciences platforms.

At Advantary, Chames sources and evaluates early-stage companies, conducts scientific and commercial diligence, and works with founders, investors, clinicians, and industry experts to assess market opportunities, technical feasibility, competitive differentiation, and strategic fit.

Chames is also the founder and CEO of AEGIS BIO, an oncology supportive-care biotechnology company developing innovative therapies intended to reduce cisplatin-related toxicities while preserving anticancer efficacy. Previously, he served as a Principal Scientist and Project Manager at Pfizer’s Centers for Therapeutic Innovation, where he led cross-functional therapeutic programs, evaluated external innovation, and managed collaborations with biotechnology companies, academic institutions, and contract research organizations. Earlier in his career, he conducted research at Stanford School of Medicine, the Institute of Human Genetics in Montpellier, and Sanofi.

His combined experience as a scientist, founder, operator, and venture professional enables him to translate complex scientific and commercial information into actionable investment recommendations and to support life sciences companies from early discovery through value-creating development milestones.

Chames earned an MBA from Babson College, a PhD in Human Genetics and Cell Biology and an MSc in Pharmaceutical Product Research and Development from the University of Montpellier, trained as a postdoctoral fellow at Stanford University and completed a PharmD from Mentouri University.

Expertise:

Scientific and commercial due diligence, venture evaluation, drug development, translational science, company creation, portfolio strategy

Sectors:

Biotechnology, biopharmaceuticals, therapeutics, healthtech, regenerative medicine, oncology, AI-enabled life sciences

Roles:

Investor, Scientist, Founder, Operator, Advisor

Location:

San Francisco Bay Area, CA

Chames Kermi, PharmD, PhD, MBA
768px-LinkedIn_logo_initials.png
  • Scientific and commercial due diligence

  • Venture evaluation and company creation

  • Drug development and translational science

  • Oncology and regenerative medicine

  • AI-enabled life sciences platforms

  • Portfolio strategy

  • Early-stage sourcing

  • Biopharmaceuticals

big-advantary_logo.png

​

Advantary, Advantary Capital Partners, Advantary Services Group, and the Advantary logos are trademarks Advantary LLC. Copyright © 2017-2026. All rights reserved. The names and logos of other companies are the respective property of those companies. Advantary claims no rights related, nor does this imply that those companies endorse Advantary. Advantary is not a FINRA Broker/Dealer and does not act in that capacity.

​

Privacy Policy

bottom of page